HLA-G may also function as a biomarker for screening potential benefit populations and evaluating therapeutic efficacy, as exemplified by a substantial reduction of HLA-G expression after chemotherapy administration, which probably arises from the increased sensitivity to chemotherapy of HLA-G+ tumor cells [128], and a higher response rate to chemotherapy in ovarian cancer patients with high HLA-G expression compared to the counterparts with low HLA-G expression [129]. This evidence concerns the gene HLA-G and ovarian carcinoma.